NLS Pharma & Kadimastem Seek FDA Meeting for Diabetes Treatment
Ticker: NCEL · Form: 6-K · Filed: Dec 19, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, partnership, drug-development, diabetes
TL;DR
NLS Pharma partner Kadimastem is pushing for FDA review of a new Type 1 Diabetes therapy.
AI Summary
On December 19, 2024, NLS Pharmaceutics Ltd. announced that its partner Kadimastem and its subsidiary iTolerance, Inc. have submitted a request to the FDA for a Pre-Investigational New Drug (Pre-IND) meeting. This meeting is to discuss an innovative treatment for Type 1 Diabetes.
Why It Matters
This filing indicates progress in the development of a new Type 1 Diabetes treatment, potentially impacting patients and the pharmaceutical landscape.
Risk Assessment
Risk Level: medium — The filing concerns a regulatory step for a new drug, which carries inherent development and approval risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Kadimastem (company) — Partner company
- iTolerance, Inc. (company) — Subsidiary
- FDA (company) — Regulatory body
- Type 1 Diabetes (medical_condition) — Disease being treated
- December 19, 2024 (date) — Date of announcement
FAQ
What is the specific innovative treatment Kadimastem and iTolerance are developing for Type 1 Diabetes?
The filing does not specify the exact nature of the innovative treatment, only that a Pre-IND meeting request has been submitted to the FDA to discuss it.
What is the significance of a Pre-IND meeting with the FDA?
A Pre-IND meeting allows drug developers to discuss their development plan with the FDA before submitting an Investigational New Drug (IND) application, providing guidance and potentially accelerating the review process.
What is the relationship between NLS Pharmaceutics Ltd. and Kadimastem?
Kadimastem is described as a partner of NLS Pharmaceutics Ltd. in the context of this announcement.
When was this press release issued and filed?
The press release was issued on December 19, 2024, and the Form 6-K filing was also made on December 19, 2024.
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release announcing the submission of a request for an FDA Pre-IND meeting by Kadimastem and iTolerance, Inc.
Filing Stats: 238 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-12-19 08:30:30
Filing Documents
- ea0225128-6k_nlspharma.htm (6-K) — 13KB
- ea022512801ex99-1_nlspharma.htm (EX-99.1) — 26KB
- 0001213900-24-110314.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 19, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2